Prescription ·Strong evidence ·Reviewed May 2026
Nebivolol is a third-generation, highly beta-1 selective adrenergic receptor blocker that is distinguished by its ability to promote endothelial nitric-oxide release, producing peripheral vasodilation in addition to standard beta-blockade. It is used primarily to treat hypertension, either alone or in combination with other antihypertensive agents. Its vasodilatory profile tends to produce a more favorable metabolic and hemodynamic effect than older beta-blockers.
The bottom line
Evidence rating strong. Most-documented uses: treatment of hypertension, reduction of systemic vascular resistance via nitric-oxide-mediated vasodilation, lowering of blood pressure with a relatively favorable metabolic profile. 2 sources indexed (1977–2021), with 6 interaction records on file.
Core mechanism
Nebivolol selectively antagonizes beta-1 adrenergic receptors, reducing heart rate, myocardial contractility, and cardiac output, and decreasing renin release from the kidney. At clinically relevant doses in extensive metabolizers it preserves high beta-1 selectivity, sparing beta-2 receptors and limiting bronchospasm and adverse metabolic effects. A defining feature is its modulation of the L-arginine/nitric-oxide pathway, stimulating endothelial nitric-oxide synthase to release nitric oxide, which causes vasodilation and lowers systemic vascular resistance. As a class effect, chronic beta-blockade can reduce endogenous coenzyme Q10 (ubiquinone) levels, partly by interfering with mitochondrial and CoQ10-dependent enzyme activity.1,2
Can be taken with or without food; absorption is not meaningfully affected by meals. Metabolism is heavily dependent on CYP2D6, so plasma levels are substantially higher in poor metabolizers.
Nutrients this medication can lower over time, and what to replace.
Beta-adrenergic blockers, including nebivolol, are recognized as a class to lower circulating coenzyme Q10 (ubiquinone). The proposed mechanism is inhibition of CoQ10-dependent enzymatic reactions and interference with CoQ10 biosynthesis or mitochondrial bioenergetic pathways, since CoQ10 and beta-blockers share structural similarity and CoQ10 participates in the same electron-transport processes the drugs can perturb. The reduction in myocardial and plasma CoQ10 has been hypothesized to contribute to some beta-blocker adverse effects.
L-Citrulline may add to the blood-pressure-lowering effect of Nebivolol.
Recommendation: Monitor blood pressure and dizziness, especially during dose changes; stop the supplement and seek advice if syncope, falls, or symptomatic hypotension occurs.
Magnesium Glycinate may add to the blood-pressure-lowering effect of Nebivolol.
Recommendation: Monitor blood pressure and dizziness, especially during dose changes; stop the supplement and seek advice if syncope, falls, or symptomatic hypotension occurs.
Berberine may lower glucose, while beta blockers can mask adrenergic warning signs of hypoglycemia such as tachycardia.
Recommendation: Use glucose monitoring if diabetic or taking glucose-lowering drugs; do not rely only on palpitations as a hypoglycemia warning sign.
Beta-blockers, including nebivolol, can inhibit CoQ10-dependent enzymes and may lower endogenous CoQ10 levels (a recognized class effect, best characterized with propranolol). Supplemental CoQ10 is generally well tolerated alongside nebivolol, but because CoQ10 may modestly lower blood pressure on its own, the combination can produce additive blood-pressure reduction in some patients.
Recommendation: Co-administration is reasonable and may help offset beta-blocker-related CoQ10 depletion, but monitor blood pressure and heart rate, especially when starting CoQ10 or adjusting the nebivolol dose. Report dizziness, lightheadedness, or unusual fatigue to the prescriber.
Garlic extract has a modest antihypertensive effect, particularly aged garlic extract, and may add to the blood-pressure-lowering action of nebivolol. The combination is generally well tolerated but can occasionally produce additive hypotension.
Recommendation: The combination is acceptable and may be intentional for blood-pressure support. Monitor blood pressure when starting or increasing garlic extract, and report dizziness or lightheadedness. No dose separation is required.
St. John's Wort is a broad inducer of drug-metabolizing enzymes. While nebivolol is primarily a CYP2D6 substrate, St. John's Wort can reduce the plasma concentrations and antihypertensive efficacy of many cardiovascular drugs through enzyme and transporter induction, potentially undermining blood-pressure control.
Recommendation: Avoid combining St. John's Wort with nebivolol where possible. If already taken together, monitor blood pressure closely; loss of control may require dose adjustment. Do not stop St. John's Wort abruptly without considering rebound changes in any co-administered medications. Consult the prescriber.
Numbered references. Citations throughout the page link here.
Nebivolol lowers blood pressure through beta-1 blockade and endothelial nitric-oxide-dependent vasodilation; dosing 5-40 mg once daily.
Several beta-adrenergic blocking agents inhibit CoQ10-dependent mitochondrial enzymes, supporting a class effect of CoQ10 depletion.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
